Skip to main content
. 2022 Apr 8;7(2):100431. doi: 10.1016/j.esmoop.2022.100431

Figure 1.

Figure 1

Clinical effectiveness of abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) naive to chemotherapy.

Radiographic progression-free survivala (rPFS) (A), PFSa (B), and overall survival (OS) (C) in the ABItude study.

CI, confidence interval; NE, not estimable.

aDuring abiraterone treatment.